NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression

Core Insights - Neuronetics, Inc. has announced two peer-reviewed publications that provide evidence of the effectiveness of transcranial magnetic stimulation (TMS) in improving depressive symptoms and highlight the superior sensitivity of the PHQ-9 assessment tool over the QIDS-SR for measuring TMS outcomes [1][2][5] Group 1: TMS Effectiveness - The first publication demonstrates that TMS induces universal improvement in depressive symptoms across various categories, suggesting a broad antidepressant effect rather than targeting specific symptoms [5][6] - The study involved 578 patients diagnosed with major depressive disorder (MDD) and showed that all three TMS protocols studied were equally effective, allowing for greater flexibility in treatment delivery [6] Group 2: Assessment Tools - The second publication compares the PHQ-9 and QIDS-SR assessment tools, revealing that the PHQ-9 is more sensitive in capturing symptom improvements and identifying higher remission rates than the QIDS-SR [6] - The findings indicate that the QIDS-SR often underreports symptoms and misclassifies patients as "non-responders," while the PHQ-9 provides a more reliable measure of depression severity [6] Group 3: Company Positioning - Neuronetics positions itself as a leader in advancing TMS therapy and mental health treatment, emphasizing its commitment to scientific research and data-driven innovation [2][7] - The company has delivered over 6.9 million NeuroStar Advanced Therapy treatments and operates Greenbrook TMS Inc. treatment centers across the U.S., further solidifying its market presence [8]